Search results
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
Digital Journal· 5 hours agoGSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and ...